U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06924762) titled 'Interleukin-2 for Refractory Chronic Spontaneous Urticaria' on Nov. 24, 2024.
Brief Summary: The goal of this clinical trial is to learn if human interleukin-2 (IL-2) works to treat moderate to severe chronic spontaneous urticaria in adults who remain symptomatic despite oral antihistamine treatment (refractory CSU). It will also learn about the safety of IL-2. The main questions it aims to answer are:
Does IL-2 alleviate the symptoms of urticaria in patients? What medical problems do participants have when given IL-2? Researchers will compare IL-2 to a placebo (a look-alike and smell-like substance that contains no IL-2) to see i...